Search details
1.
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Lancet Oncol
; 21(12): e575-e588, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33271114
2.
End of an era for erythropoiesis-stimulating agents in oncology.
Int J Cancer
; 146(10): 2829-2835, 2020 05 15.
Article
in English
| MEDLINE | ID: mdl-32037527
3.
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).
EClinicalMedicine
; 31: 100693, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33554084
4.
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et al.
Expert Opin Drug Saf
; 19(8): 1057-1058, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32364807
5.
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
PLoS One
; 15(6): e0234541, 2020.
Article
in English
| MEDLINE | ID: mdl-32584835
6.
An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.
Expert Opin Drug Saf
; 18(11): 1055-1063, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31500468
7.
Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.
PLoS One
; 14(7): e0219521, 2019.
Article
in English
| MEDLINE | ID: mdl-31365527
Results
1 -
7
de 7
1
Next >
>>